Russian guidelines for the management of COPD: algorithm of pharmacologic treatment [Corrigendum]

Abstract

Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M. Int J Chron Obstruct Pulmon Dis. 2018;13:183–187.Page 186, Disclosure, the text “The authors report no conflicts of interest in this work” should read “SA has received speaker/consultancy fees from Boehringer Ingelheim, AstraZeneca, Chiesi, Teva and Novartis; non-financial support from Boehringer Ingelheim, Chiesi and Novartis; and research grants from AstraZeneca, GlaxoSmithKline and Novartis. MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharm, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. ZA has received speaker/consultancy fees from Boehringer Ingelheim, AstraZeneca, Chiesi, Teva and Novartis, GlaxoSmithKline; non-financial support from Boehringer Ingelheim, GSK and Novartis; and research grants from AstraZeneca, GlaxoSmithKline and Novartis. The authors report no other conflicts of interest in this work”.Read the original article